ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO027

Outcomes Among Hospitalized Patients With COVID-19 and AKI: Role of SARS-CoV-2 Vaccine

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Torres Cuevas, Jose Luis, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Martinez-Sanchez, Froylan David, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Gonzalez Sanchez, Hector Raul, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Saenz-Ancira, Santiago, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Reyna Juárez, Yatzil, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Diaz-Jarquin, Alejandra, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Romero-Reyes, Carlos Alberto, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Ibarra Santoyo, Luis Alberto, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Juarez, Joana Balderas, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Salinas-Ramirez, Mauricio Adrian, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
  • Tenorio-Aguirre, Erika Karina, Hospital General Dr Manuel Gea Gonzalez, Ciudad de Mexico, Ciudad de México, Mexico
Background

COVID-19 and Acute kidney injury (AKI) are associated with increased mortality and worse kidney outcomes. Although vaccines against SARS-CoV-2 have decreased the rate COVID-19 morbimortality, the role of immune protection against SARS-CoV-2 in the setting of AKI has not been fully yielded

Methods

Retrospective case-control study that included clinical and biochemical data of 412 (78 vaccinated and 334 non-vaccinated) patients with severe COVID-19. Cox regression analyses were used to evaluate the effect of the vaccine in mortality and AKI outcomes

Results

The mean age of the patients was 55±15 years, 64% were women, the mean body mass index was 28±5 kg/m2, and median in-hospital stay was 10(6-16) days. The rate of mortality and AKI 3 was 29% vs 10% and 27% vs 13%, for unvaccinated and vaccinated patients, respectively. Cox proportional hazard ratios for survival and prevention of AKI are shown in table 1

Conclusion

The SARS-CoV-2 vaccine was independently associated with lower mortality and AKI progression in patients with severe COVID-19

Table 1. Cox proportional hazard model of SARS-CoV-2 vaccination and the risk for mortality, development of Acute Kidney Injury (AKI), and AKI stage 3
 Mortality  AKI 1-3* AKI 3* 
SARS-CoV-2 VaccineHR (95%CI)p valueHR (95%CI)p valueHR (95%CI)p value
Unadjusted0.382 (0.185-0.785)0.0090.629 (0.441-0.897)0.0100.528 (0.274-1.017)0.056
Model 1
0.348 (0.168-0.719)0.0040.597 (0.418-0.853)0.0050.498 (0.256-0.967)0.040
Model 20.440 (0.211-0.919)0.0290.585 (0.407-0.842)0.0040.464 (0.234-0.919)0.028
Model 30.444 (0.213-0.927)0.0310.534 (0.368-0.776)0.0010.493 (0.246-0.985)0.045

Model 1 was adjusted by age, sex, and Body Mass Index; model 2 included model 1 plus type 2 diabetes, blood pressure >140/90 mmHg, chronic kidney disease, renal replacement therapy, and AKI 3; and model 3 included model 2 plus serum levels of D-dimer, lactic dehydrogenase, C-reactive protein, and ferritin. * In model 2 variable AKI 3 was not included in the Cox regression analysis.